CD69 and plasma cell myeloma: Tracing BM-resident CD69+ TTE within MILs and correlating their numbers with clinical outcome in MM patients receiving MILs as adoptive T-cell therapy (45) could provide essential insights into the role of BM-resident CD69+ TTE in myeloma immunity.